This website uses cookies

We use cookies to personalize content and ads, to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. We will only use cookies based on your decision.

CK-MB mass

The Acute Care™ CK-MB assay is an in vitro diagnostic test for the measurement of the MB iso-enzyme of creatine kinase in heparinized whole blood/plasma. CK-MB measurements can be used as an aid in diagnosing acute myocardial infarction.
 

Clinical Significance
CK-MB is found primarily in cardiac tissue.1 CK-MB can be detected at elevated concentrations following myocardial damage. Abnormal plasma CK-MB concentrations are often associated with ischemia or necrotic heart injury. The increase in CK-MB concentration is often evident within 3 to 6 hours following onset of chest pain, reaching peak concentrations within 12 to 24 hours. CK-MB concentrations will generally return to normal within 24 to 72 hours.2 The determination of CK-MB is most beneficial when samples have been drawn at appropriate time intervals post onset of chest pain.

Delivering What Matters:

  • One sample, one run, one instrument; increases efficiency in triaging chest pain patients
  • Rapid turnaround time - in as little as 14 min. (with onboard centrifugation)
  • Single and ready to use TestPak™ Cartridges
    • No reconstitution
    • No warming to room temperature
    • Reduction in reagent waste
    • Reduction in contamination
  • Heparinized whole blood samples
  • Electronic QC (System Check) satisfies daily routine QC requirements permitting liquid QC flexibility

For additional information on CK-MB mass visit our educational website at

1
2
Subscription Button Icon
Be the first to know about our events, training, and news